Cargando…

Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer

BACKGROUND: Sentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the management of early breast cancer. When SLN is free of metastasis, complete axillary dissection may be skipped for staging in clinically N0 patients, allowing a more conservative procedure. Histological tumor f...

Descripción completa

Detalles Bibliográficos
Autores principales: Britto, Anna V, Schenka, André A, Moraes-Schenka, Natália G, Alvarenga, Marcelo, Shinzato, Júlia Y, Vassallo, José, Ward, Laura S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674880/
https://www.ncbi.nlm.nih.gov/pubmed/19356249
http://dx.doi.org/10.1186/1471-2407-9-109
_version_ 1782166670849081344
author Britto, Anna V
Schenka, André A
Moraes-Schenka, Natália G
Alvarenga, Marcelo
Shinzato, Júlia Y
Vassallo, José
Ward, Laura S
author_facet Britto, Anna V
Schenka, André A
Moraes-Schenka, Natália G
Alvarenga, Marcelo
Shinzato, Júlia Y
Vassallo, José
Ward, Laura S
author_sort Britto, Anna V
collection PubMed
description BACKGROUND: Sentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the management of early breast cancer. When SLN is free of metastasis, complete axillary dissection may be skipped for staging in clinically N0 patients, allowing a more conservative procedure. Histological tumor features that could reliably predict SLN status have not yet been established. Since the degree of tumor lymphangiogenesis and vascularization may theoretically be related to the risk of lymph node metastasis, we sought to evaluate the relationship between lymph vessel invasion (LVI), lymphatic microvascular density (LVD), microvascular density (MVD) and VEGF-A expression, with SLN status and other known adverse clinical risk factors. METHODS: Protein expression of D2–40, CD34, and VEGF-A was assessed by immunohistochemistry on paraffin-embedded sections of primary breast cancer specimens from 92 patients submitted to SLN investigation. The presence of LVI, the highest number of micro vessels stained for D2–40 and CD34, and the protein expression of VEGF-A were compared to SLN status, clinicopathological features and risk groups. RESULTS: LVI was detected in higher ratios by immunostaining with D2–40 (p < 0.0001), what would have changed the risk category from low to intermediate in four cases (4.3%). There was no association between LVI and other angiogenic parameters determined by immunohistochemistry with SLN macrometastases, clinical features or risk categories. CONCLUSION: Assessment of LVI in breast carcinoma may be significantly increased by immunostaining with D2–40, but the clinical relevance of altering the risk category using this parameter may not be advocated according to our results, neither can the use of LVI and LVD as predictors of SLN macrometastasis in early breast cancer.
format Text
id pubmed-2674880
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26748802009-04-30 Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer Britto, Anna V Schenka, André A Moraes-Schenka, Natália G Alvarenga, Marcelo Shinzato, Júlia Y Vassallo, José Ward, Laura S BMC Cancer Research Article BACKGROUND: Sentinel lymph node (SLN) biopsy is a widely used diagnostic procedure in the management of early breast cancer. When SLN is free of metastasis, complete axillary dissection may be skipped for staging in clinically N0 patients, allowing a more conservative procedure. Histological tumor features that could reliably predict SLN status have not yet been established. Since the degree of tumor lymphangiogenesis and vascularization may theoretically be related to the risk of lymph node metastasis, we sought to evaluate the relationship between lymph vessel invasion (LVI), lymphatic microvascular density (LVD), microvascular density (MVD) and VEGF-A expression, with SLN status and other known adverse clinical risk factors. METHODS: Protein expression of D2–40, CD34, and VEGF-A was assessed by immunohistochemistry on paraffin-embedded sections of primary breast cancer specimens from 92 patients submitted to SLN investigation. The presence of LVI, the highest number of micro vessels stained for D2–40 and CD34, and the protein expression of VEGF-A were compared to SLN status, clinicopathological features and risk groups. RESULTS: LVI was detected in higher ratios by immunostaining with D2–40 (p < 0.0001), what would have changed the risk category from low to intermediate in four cases (4.3%). There was no association between LVI and other angiogenic parameters determined by immunohistochemistry with SLN macrometastases, clinical features or risk categories. CONCLUSION: Assessment of LVI in breast carcinoma may be significantly increased by immunostaining with D2–40, but the clinical relevance of altering the risk category using this parameter may not be advocated according to our results, neither can the use of LVI and LVD as predictors of SLN macrometastasis in early breast cancer. BioMed Central 2009-04-08 /pmc/articles/PMC2674880/ /pubmed/19356249 http://dx.doi.org/10.1186/1471-2407-9-109 Text en Copyright ©2009 Britto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Britto, Anna V
Schenka, André A
Moraes-Schenka, Natália G
Alvarenga, Marcelo
Shinzato, Júlia Y
Vassallo, José
Ward, Laura S
Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title_full Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title_fullStr Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title_full_unstemmed Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title_short Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
title_sort immunostaining with d2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674880/
https://www.ncbi.nlm.nih.gov/pubmed/19356249
http://dx.doi.org/10.1186/1471-2407-9-109
work_keys_str_mv AT brittoannav immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT schenkaandrea immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT moraesschenkanataliag immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT alvarengamarcelo immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT shinzatojuliay immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT vassallojose immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer
AT wardlauras immunostainingwithd240improvesevaluationoflymphovascularinvasionbutmaynotpredictsentinellymphnodestatusinearlybreastcancer